Alpha toxin (AT) is a cytolytic pore-forming toxin that plays a key role in Staphylococcus 11 aureus pathogenesis, consequently extensive research was undertaken to understand the AT 12 mechanism of action and its utility as a target for novel prophylaxis and treatment strategies 13 against S. aureus infections. MEDI4893 (Suvratoxumab) is a human anti-AT IgG1 monoclonal 14 antibody (mAb), which targets AT and is currently in Phase 2 clinical development. As shown 15 previously, the MEDI4893-binding epitope on AT is comprised of the highly conserved amino 16 acid regions 177-200 and 261-271, suggesting these amino acids are important for AT function. 17 To test this hypothesis, and gain insight into the effect mutations in the epitope on AT 18 neutralization by MEDI4893, nine MEDI4893 contact residues in AT were individually mutated 19 to alanine. Consistent with our hypothesis, 8 out of 9 mutants exhibited >2-fold loss in lytic 20 activity resulting from a defect in cell binding and pore formation. MEDI4893 binding affinity 21 was reduced >2-fold (2 -27-fold) for 7 out of 9 mutants and no binding detected for W187A 22 mutant. MEDI4893 effectively neutralized all of the lytic mutants in vitro and in vivo. When the 23 defective mutants were introduced into a S. aureus clinical isolate, the mutant-expressing strains 24 exhibited less severe disease in mouse models and were effectively neutralized by MEDI4893.
Introduction
Walker et. al. previously reported that amino acid R200 is important for AT binding to 142 cell membranes (31) . To determine if the other epitope residues were also important for cell 143 binding, the mutant toxins were biotinylated and binding to A549 cells was measured by flow 144 cytometry (23) and compared with WT-AT and the oligomerization defective mutant, H35L. 145 Similar to the A549 lysis results, AT mutants D183A, P189A, V190A, T263A and K266A 146 exhibited reduced cell binding relative to WT-AT or H35L, whereas no binding was detected 147 with the mutants (W187A, N188A or R200A) most defective for A549 lysis (Fig. 6, Table S1 ), 148 indicating the residues comprising the MEDI4893 epitope are important for cell binding. 149 Consistent with the MEDI4893 neutralization of AT mutant-mediated lysis (Fig. 3) , the mAb 150 effectively blocked detectable cell binding by all mutants (Fig. 6) .
151
MEDI4893 binding affinity to AT mutants 152 The results above indicated MEDI4893 effectively neutralized the lytic alanine mutants 153 in vitro and in vivo. To further characterize the interaction of MEDI4893 with the epitope 154 mutants, mAb association (k on ) and dissociation (k off ) constants for each mutant were measured 155 by surface plasmon resonance and the affinity constant (K D ) for each variant was calculated. 156 Although the mAb exhibited a modest drop in K D to D183A, S186A, V190A and T263A it 157 retained a sub-nanomolar K D , however antibody binding constants to N188A, P189A, R200A 158 and K266A were reduced >10-fold (11-to 26-fold) and no binding to W187A was detected in 159 the assay. These data showed a direct correlation between decreased neutralization of AT 160 mutants in the hemolytic assay and their loss for affinity to MEDI4893 ( AT mutants, four mutants (N188A, W187A, R200, K266A) exhibited at least a 15-fold loss of 166 binding by MEDI4893 (Table 1) . To determine if the mAb prevented disease caused by S. 167 aureus strains expressing the mutant toxins with the greatest loss in binding affinity, the alanine 168 mutants were introduced into the USA300 CA-MRSA SF8300 chromosome by allelic exchange.
169
Each mutant was confirmed to express equivalent toxin levels in vitro (Fig. S3) . Balb/c mice 170 (n=10) were passively immunized with MEDI4893* (10mpk) or an isotype control IgG (c-IgG) 171 24h prior to ID inoculation with each strain (5e7cfu) and lesion sizes were measured 24h post 172 infection. Consistent with the in vitro lysis and toxin mediated dermonecrosis results above, the 173 strains expressing N188A, W187A and K266A were less virulent and formed smaller lesions 174 than infection with WT SF8300 and the strain expressing the least lytic mutant R200A was 175 avirulent in this model. Also, MEDI4893* prophylaxis inhibited dermonecrosis caused by the 176 mutant-expressing strains, resulting in lesions resembling infection with an S. aureus hla. . S4 ). The AT mutant-expressing strains were similarly avirulent in the murine 178 pneumonia model except for SF8300-N188A which caused disease similar to WT SF8300.
179
Despite a ~16-fold drop in binding affinity for N188A, MEDI4893* prophylaxis significantly 180 reduced death following infection with the N188A mutant strain (Fig. 8) . Collectively, these 181 data demonstrate that the AT AAs comprising the MEDI4893-binding epitope are essential not 182 only for AT function, but also for S. aureus fitness in vivo and that MEDI4893* can neutralize 183 the toxic effects of AT even when its epitope is mutated and its binding affinity reduced. The current antibiotic resistance problem has been fueled by widespread use and misuse 186 of broad spectrum antibiotics. Coupled with a greater understanding of the adverse effects that 187 empiric broad-spectrum antibiotic therapy has on the healthy microbiome, there has been an 188 increasing effort to identify alternative strategies to treat infections with antibiotic resistant 189 pathogens. One emerging approach is the use of mAbs to either prevent or treat resistant 190 bacterial infections (1, 32) . Although several antibacterial mAb-based treatment strategies are 191 currently in clinical testing, little information is available about resistance to these molecules.
192
Antibacterial childhood vaccines (e.g. diphtheria, tetanus, and pertussis, Hemophilus influenzae 193 type b, Streptococcus pneumoniae) which rely on a functional antibacterial antibody response 194 have been in use for years or even decades with no apparent emergence of resistance (33). This 195 lack of resistance is likely due in part to the polyclonal antibody response generated by the 196 vaccines and may not predict a similar outcome for an antibacterial mAb.
197
Unlike antibiotics which kill bacteria and exert direct selective pressure on bacteria, 198 mAb-based antibacterial approaches either neutralize bacterial virulence factors, promote a 199 protective immune response or target the bacteria for opsonophagocytic killing by host immune 200 cells (2, 34). Consequently, the host immune system is responsible for killing the bacteria, not 201 the mAb (35). Since mAbs do not affect bacterial growth directly, it is difficult or even 202 impossible to study the emergence of resistance in vitro or in vivo over the time course of 203 preclinical infection models. To begin to address the questions about circulating resistant S. 204 aureus isolates, we conducted two studies in which the AT gene (hla) was sequenced from 205 ~1,250 clinical isolates (24-26). In these collections, 58 different AT sequence types were 206 identified and the anti-AT mAb MEDI4893, currently in Phase 2 clinical testing, effectively 207 neutralized all lytic variants. Of these clinical isolates, only 19 encoded an AT protein with a 208 11 mutation in the MEDI4893 epitope which was effectively neutralized. During Phase 1 study, no 209 AT variants with amino acid substitutions in MEDI4893-binding region were detected despite 210 prolonged exposure of S. aureus strains to MEDI4893 due to its extended half-life (26). Because 211 the MEDI4893 epitope is highly conserved and no MEDI4893-resistant mutants were observed 212 thus far, we hypothesized that the AT AAs in the MEDI4893-binding epitope are important for 213 AT function.
214
In the current study, we mutated 9 AA contact residues in the MEDI4893 epitope to 215 alanine to characterize their roles in AT lytic activity and S. aureus fitness and to gain insight of 216 these mutations on MEDI4893 binding and neutralization. Consistent with published results 217 indicating that residue R200 found in the epitope was important for AT cell lysis (31), lytic 218 activity was decreased ≥2-fold in 8 out of 9 mutants constructed herein and of these, 3 mutants 219 lost ≥10-fold of their lytic activity on rabbit RBC or the A549 lung epithelial cell line (Fig.2 , 220   Table S1 ). This loss in toxin activity in vitro translated into a similar loss in activity in vivo 221 resulting in reduced virulence in both skin and lung infection models. These results support the 222 hypothesis that the MEDI4893 epitope in AT is important not only for AT lytic activity, but also 223 for bacterial fitness in skin and lung infection models. Therefore, it is not surprising that only 224 two MEDI4893 epitope variants (N188T and V190I) were identified in the collection of ~1,250 225 bloodstream and lung infection clinical isolates (24) (25) (26) . Although the potential for emergence of 226 MEDI4893 resistance appears to be low, further monitoring of AT sequence variants encoded by 227 circulating clinical isolates is underway that will provide added information regarding AT 228 sequence conservation and the fitness of strains expressing defective or inactive AT variants.
229
MEDI4893 is an affinity optimized variant of the anti-AT mAb 2A3 (20, 21). When 2A3 230 was identified, its in vitro and in vivo neutralizing activity strongly correlated with mAb affinity 231 for the toxin (20). This finding led to an affinity optimization campaign to increase affinity that 232 would hopefully translate into increased potency and protective capacity in vivo. Although 2A3 233 was successfully optimized into MEDI4893 with ~10-fold increased binding affinity (0.60 nM 234 K D for 2A3 and ~0.089 nM K D for MEDI4893) there was no improvement in neutralization 235 activity or protection in preclinical disease models (13, 20, 29) . However, the improved 236 MEDI4893 binding affinity may have been beneficial regarding its ability to compensate for Alanine mutant hla expression plasmids were prepared by cloning synthetic DNA fragments 252 containing the mutations into the wild-type expression construct. The alanine mutant plasmids 253 were introduced into S. aureus RN4220hla by electroporation and selected on medium 254 13 containing 10 g/mL chloramphenicol. Mutant-expressing strains were cultured overnight at 255 37°C in BHI (brain heart infusion) broth (Criterion, Inc) with 10 g/mL chloramphenicol and AT 256 proteins were purified from culture supernatants by cation exchange chromatography using an 257 SP-HP column (GE Healthcare) equilibrated with 30mM Na acetate, pH 5.2, 20mM NaCl, 1mM 258 EDTA and eluted with a linear gradient to 500 mM NaCl.
259
Rabbit red blood cell hemolytic assay 260 Rabbit red blood cell (RBC) hemolytic assay was performed as described (20) . Briefly, wild-261 type AT (WT-AT) or AT mutants were serially diluted two-fold in 50l starting at 10g/ml, and Erythrocyte ghosts were prepared as described previously (20) from rabbit blood (Peel Freez).
281
Briefly, 5ml of packed RBC were washed twice in 0.9% NaCl and incubated in 90ml of lysis series. Select buffer injections were used along with the reference cell responses to correct the 310 raw data sets for injection artifacts and/or nonspecific binding interactions, commonly referred to 311 as "double referencing". Fully corrected binding data were then globally fit to a 1:1 binding 312 model (BIAevaluation 4.1 software; BIAcore, Inc.) that included a term to correct for possible 313 mass transport-limited binding. These analyses determined the kinetic rate constants k on and k off , 314 from which the apparent dissociation constant (KD) was calculated as k off /k on .
315
Alpha toxin binding by cytofluorimetry 316 AT binding to A549 cells, and inhibitory effect of MEDI4893 was measured as previously 317 described (23) with some modifications. Briefly, AT mutants or WT were biotinylated using the 318 EZ link Sulfo-NHS-LC biotinyaltion kit (Thermo Fisher Scientific) following manufacturer 319 protocol. All incubations and washes were performed in FACS buffer (PBS, 0.5% BSA, 0.1% 320 Tween). AT and MEDI4893* were pre-incubated for 30min at room temperature at a molar ratio 321 16 1:5. Cells were first blocked in with human Fc blocker (eBioscience), then incubated for 1h at 322 4°C with AT alone or MEDI4893-AT mix. Following one wash, cells were then incubated for 323 30min at 4°C with Streptavidin FITC conjugate (eBioscience). After two washes, AT binding 324 was then quantified with a LSRII flow cytometer (BD Biosciences) and data analyzed with Flow 325 Jo Software (Tree Star, Inc., Ashland, OR).
326
Chromosomal allelic exchange of hla alanine mutants in strain SF8300
327
Alanine mutation-containing sequences were subcloned into temperature sensitive allelic 328 exchange vector pBD100 (Binh Diep, UCSF). Constructs were transferred from strain RN4220 Lethal pneumonia was induced as reported previously (13). Six-week-old female C57/B6 mice 343 (Jackson) were passively immunized with MEDI48938 (15mpk) or c-IgG, and intra-nasally 344 infected 24h later with SF8300 WT or SF8300 expressing AT alanine mutants (1.5e8cfu in 345 50l). Animal survival was monitored over 6 days post infection. intradermal infection with S. aureus SF8300 or the SF8300 hla knock-in mutants (5e7cfu).
522
Lesion sizes were measured 24h post infection. 523 Fig. 8 : MEDI4893* inhibits USA300 knock-in mutant virulence in pneumonia. C57/B6 mice 524 mice (n=10) were passively immunized with MEDI4893* or c-IgG (15mpk), and infected 525 intranasally with 1.3e8cfu of WT, ∆hla or hla knock-in mutant SF8300. Survival was followed 526 over 6 days post-challenge. 527 Table 1 : Association and dissociation rate constant and apparent binding constants of 528 MEDI4893 to AT alanine mutants. Association (k on ) and dissociation (k off ) rate constants were 529 measured using a BIAcore instrument, and apparent binding constant (K D ) was calculated as 530 k on /k off 531 Table 1 : Association and dissociation rate constant and apparent binding constants of MEDI4893 to AT alanine mutants. Association (k on ) and dissociation (k off ) rate constants were measured using a BIAcore instrument, and apparent binding constant (K D ) was calculated as k on /k off
